Skip to main content

Advertisement

Table 2 Major clinical parameters during the trial

From: Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

  Baseline 4 weeks 8 weeks 12 weeks
sUA, μmol/L
 Febuxostat 561.10 ± 71.63 405.43 ± 78.20## 429.41 ± 94.71## 404.27 ± 81.10##
 Benzbromarone 554.90 ± 66.73 381.58 ± 92.8## 400.57 ± 79.91## 390.91 ± 92.87##
CCr, mL/min
 Febuxostat 105.93 ± 30.61 108.17 ± 32.14 108.61 ± 30.73 110.87 ± 30.93##,*
 Benzbromarone 108.86 ± 29.12 108.25 ± 27.27 108.15 ± 28.41 108.08 ± 28.78
Cr, μmol/L
 Febuxostat 84.21 ± 15.10 82.39 ± 14.65# 83.38 ± 14.55 80.83 ± 15.13##,*
 Benzbromarone 81.13 ± 12.19 81.63 ± 12.03 79.83 ± 9.82 82.14 ± 12.48
BUN, mmol/L
 Febuxostat 5.56 ± 1.21* 5.66 ± 1.19 5.69 ± 1.39 5.59 ± 1.45
 Benzbromarone 5.02 ± 1.40 4.84 ± 1.33 5.00 ± 1.36 5.83 ± 7.90
TG, mmol/L
 Febuxostat 1.70 ± 0.65 1.98 ± 0.85#,** 2.03 ± 1.15#,* 1.97 ± 0.89*
 Benzbromarone 1.93 ± 0.93 1.81 ± 0.89 1.95 ± 1.04 1.87 ± 0.85
TC, mmol/L
 Febuxostat 4.95 ± 0.93 4.94 ± 0.95 4.89 ± 0.88 5.02 ± 0.87
 Benzbromarone 5.21 ± 0.98 5.12 ± 0.91 5.27 ± 0.92 5.20 ± 0.88
ALT, U/L
 Febuxostat 32.45 ± 15.96 43.77 ± 22.10##,** 42.73 ± 24.13##,** 42.88 ± 24.20##,*
 Benzbromarone 27.74 ± 13.87 29.96 ± 19.74 28.05 ± 15.18 30.08 ± 20.94
AST, U/L
 Febuxostat 22.90 ± 11.38 26.97 ± 11.22##,* 25.365 ± 7.88## 27.32 ± 14.59##,**
 Benzbromarone 22.16 ± 6.87 22.88 ± 9.76 22.21 ± 7.63 22.75 ± 8.64
GLU, mmol/L
 Febuxostat 5.76 ± 0.57 5.63 ± 0.60 5.73 ± 0.66 5.74 ± 0.75
 Benzbromarone 5.76 ± 0.93 5.67 ± 1.03 5.65 ± 0.59 5.80 ± 0.94
  1. Data given as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, Feb group vs. Ben group. #P ≤ 0.05, ##P ≤ 0.01, before vs. after treatment